- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04490681
Validation of ERTugliflozin for Inhibiting Cardiac Fibrosis Using Cardiac MRI and Laboratory Parameters in Korean Heart Failure Patients With Nonischemic Cardiomyopathy(VERTICAL)
Based on recent studies demonstrating SGLT2 inhibitors' favorable effects on cardiovascular outcomes especially for heart failure, the investigators hypothesize that sodium-glucose co-transporter-2 (SGLT2) inhibitor, ertugliflozin, is effective on reducing cardiac fibrosis in patients with nonischemic cardiomyopathy so the investigators try to examine this hypothesis in a single-center, double-blind, randomized controlled study using cardiac magnetic resonance (CMR).
This study is a prospective, single-center, randomized, double-blind, two arm parallel group, placebo-controlled clinical trial involving patients with nonischemic cardiomyopathy. Patients meeting inclusion criteria without any exclusion criteria will be randomized 1:1 to ertugliflozin or placebo therapy, and cardiovascular functional assessment and clinical event follow-up will be undertaken.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Iscrizione (Anticipato)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Seoul, Corea, Repubblica di
- Severance Hospiatal
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients must agree to the study protocol and provide written informed consent
- Outpatients ≥ 19 years, <75 years of age, male or female
- Non-diabetic or type 2 DM patients with HbA1c 7.0-10.5%
- Patients with nonischemic cardiomyopathy (LVEF ≤40%)
- Exclusion of ischemic origin cardiomyopathy using coronary angiography or CT angiography or SPECT scan (e.g. significant stenosis of proximal LAD or left main & myocardial infarction)
- Dyspnea of NYHA functional class II or III
- NT-proBNP ≥ 400 pg/ml (≥ 900 pg/ml if atrial fibrillation or atrial flutter)
- Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB or ARNI if indicated) for at least 4 weeks prior to study entry
Exclusion Criteria:
- History of hypersensitivity or allergy to the study drug, drugs of similar chemical classes, or SGLT-2 as well as known or suspected contraindications to the study drug
- Current use or prior use of a SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor
- Known history of angioedema
- Current acute decompensated heart failure or dyspnea of NYHA functional class IV
- Medical history of hospitalization within 6 weeks
- Acute coronary syndrome, stroke, major CV surgery, PCI within 3 months
- Substantial myocardial ischemia requiring coronary revascularization therapy or a plan of coronary revascularization within 6 months
- A plan of heart transplantation or implantation of cardiac resynchronization therapy
- Symptomatic hypotension and/or a SBP < 95 mmHg at screening
- Estimated GFR < 30 mL/min/1.73m2
- History of ketoacidosis
- Symptomatic peripheral artery disease and history of lower limb amputation
- Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 3 x upper limit of normal (ULN) at screening visit (Visit 0), history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt.
- History of severe pulmonary disease
- Significant mitral & aortic valve disease (e.g. moderate to severe, severe degree)
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using a barrier method plus a hormonal method
- Pregnant or nursing (lactating) women
- Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the investigator, would preclude safe completion of the study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore placebo: placebo
Placebo
|
Gruppo placebo
|
Sperimentale: Ertugliflozin
Ertugliflozin 5mg
|
Fixed dose Ertugliflozin (5mg)
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
The ECV value change in CMR after Drug (Ertugliflozin or Placebo) administration
Lasso di tempo: Baseline
|
The ECV value change in MRI from baseline to End of trial (48 weeks)
|
Baseline
|
The ECV value change in CMR after Drug (Ertugliflozin or Placebo) administration
Lasso di tempo: 48 Weeks after drug administration
|
The ECV value change in MRI from baseline to End of trial (48 weeks)
|
48 Weeks after drug administration
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
CMR parameters : ECV (%)
Lasso di tempo: baseline
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
baseline
|
CMR parameters : ECV (%)
Lasso di tempo: 12 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
12 weeks after drug administration
|
CMR parameters : ECV (%)
Lasso di tempo: 48 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
48 weeks after drug administration
|
CMR parameters : Native T1 (ms)
Lasso di tempo: baseline
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
baseline
|
CMR parameters : Native T1 (ms)
Lasso di tempo: 12 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
12 weeks after drug administration
|
CMR parameters : Native T1 (ms)
Lasso di tempo: 48 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
48 weeks after drug administration
|
CMR parameters : left & right ventricular (LV & RV) mass index (g/m2)
Lasso di tempo: Baseline
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
Baseline
|
CMR parameters : left & right ventricular (LV & RV) mass index (g/m2)
Lasso di tempo: 12 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
12 weeks after drug administration
|
CMR parameters : left & right ventricular (LV & RV) mass index (g/m2)
Lasso di tempo: 48 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
48 weeks after drug administration
|
CMR parameters : LV & RV ejection fraction (%)
Lasso di tempo: Baseline
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
Baseline
|
CMR parameters : LV & RV ejection fraction (%)
Lasso di tempo: 12 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
12 weeks after drug administration
|
CMR parameters : LV & RV ejection fraction (%)
Lasso di tempo: 48 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
48 weeks after drug administration
|
CMR parameters : LV & RV end-systolic volume, LV & RV end-diastolic volume (ml)
Lasso di tempo: Baseline
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
Baseline
|
CMR parameters : LV & RV end-systolic volume, LV & RV end-diastolic volume (ml)
Lasso di tempo: 12 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
12 weeks after drug administration
|
CMR parameters : LV & RV end-systolic volume, LV & RV end-diastolic volume (ml)
Lasso di tempo: 48 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
48 weeks after drug administration
|
CMR parameters : cine-base cardiac strain (%)
Lasso di tempo: Baseline
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
Baseline
|
CMR parameters : cine-base cardiac strain (%)
Lasso di tempo: 12 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
12 weeks after drug administration
|
CMR parameters : cine-base cardiac strain (%)
Lasso di tempo: 48 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
48 weeks after drug administration
|
Biomarkers : NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7
Lasso di tempo: baseline
|
The change in degree of NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7 after drug administration.
|
baseline
|
Biomarkers : NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7
Lasso di tempo: 12 weeks after drug administration
|
The change in degree of NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7 after drug administration.
|
12 weeks after drug administration
|
Biomarkers : NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7
Lasso di tempo: 24 weeks after drug administration
|
The change in degree of NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7 after drug administration.
|
24 weeks after drug administration
|
Biomarkers : NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7
Lasso di tempo: 48 weeks after drug administration
|
The change in degree of NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7 after drug administration.
|
48 weeks after drug administration
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Anticipato)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 4-2020-0484
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .